Daclatasvir Is A Direct Effect On Hepatitis C Virus Antiviral

  Daclatasvir is a direct effect on hepatitis C virus antiviral (DAA).

  【Indications and uses】

  Daclatasvir is a hepatitis C virus (HCV) NS5A inhibitor suitable for use with sufubitaine [sofosbuvir] for the treatment of chronic HCV genotype 3 infection.

  【Dosage and Specification】

  Tablets: 30 mg and 60 mg

  [Dosage and Administration]

  ⑴ 60mg orally once a day or no food with the combination of sofloxacin.

  ⑵ recommended treatment time: 12 weeks.

  ⑶ Dose Modification with strong CYP3A inhibitor reduced dose to 30 mg once daily and with moderate CYP3A inducer to increase the dose to 90 mg once daily.

  Contraindications

  CYP3A strong inducers, including phenytoin, carbamazepine, rifampin, and St. John's wort.

  【Warning and Precautions】

  Bradycardia when administered in combination with sufiboxibir and amiodarone: A severe symptomatic bradycardia may occur in patients taking amiodarone and sofloxacin in combination with another HCV direct drug, including Daclatasvir (daclatasvir ), In particular, beta-blockers or those with potential cardiac comorbidities and / or advanced liver disease.

  It is suggested that amiodarone should not be administered in combination with Daclatasvir and sofloxacin. It is recommended to monitor the heart in patients without additional treatment options.